Divalproex Sodium
Product Images NDC 67296-1635

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 67296-1635). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Sdistributi19051016030 0001)

Label for Divalproex Sodium ER 250 mg tablets, containing 10 tablets per package. The label states 'Rx Only' and includes a barcode. It shows storage instructions at controlled room temperature (20-25°C), lot number 12786A1, and expiration date 03/19. Manufactured for Impax Generics, Hayward, CA, and distributed by RedPharm Drug, Eden Prairie, MN.*

FDA Label Image

Chemical Structure (Divalproex Sodium Extended Release Tablets 1)

Chemical structure diagram of divalproex sodium, showing its molecular components and arrangement, including sodium ion and organic groups.*

FDA Label Image

Dvp Figure 1 (Divalproex Sodium Extended Release Tablets 2)

A cumulative distribution chart comparing % reduction in CPS rate between Divalproex Sodium Delayed-Release Tablets and placebo. The horizontal axis shows % of patients from 0 to 100, and the vertical axis shows % reduction CPS rate ranging from -100% to 100%. The graph indicates trends of improvement and worsening, with solid and dotted lines representing Divalproex Sodium and placebo, respectively.*

FDA Label Image

Figure 2 (Divalproex Sodium Extended Release Tablets 3)

A cumulative distribution plot showing the percentage reduction in complex partial seizure (CPS) rate among patients taking Divalproex Sodium delayed-release tablets. The graph compares two groups: high dose (solid line) and low dose (dotted line), with patient percentage on the x-axis and CPS rate reduction on the y-axis. Arrows indicate improvement and worsening directions.*

FDA Label Image

Figure 3 (Divalproex Sodium Extended Release Tablets 4)

A bar graph comparing the effects of Placebo and Divalproex Sodium Extended-Release Tablets. The graph shows a higher value for Divalproex Sodium Extended-Release Tablets (1.2) compared to Placebo (0.6). An asterisk indicates a statistically significant difference with p=0.006.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.